Introductory Chapter: Clostridium difficile Infection Overview by Enany, Shymaa
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
Chapter 1
Introductory Chapter: Clostridium difficile Infection
Overview
Shymaa Enany
Additional information is available at the end of the chapter
http://dx.doi.org/10.5772/intechopen.69983
© 2016 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons 
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, 
and reproduction in any medium, provided the original work is properly cited. 
Clostridium difficile
Shymaa Enany
Additional information is available at the end of the chapter
1. Introduction
Clostridium difficile (C. difficile) is an anaerobic, spore‐forming Gram‐positive bacillus that was 
first described in 1935 as part of the intestinal microflora in neonates, even so it was not identi‐
fied as a causative agent of human disease until 1978 [1]. The clinical presentation of C. difficile 
infection (CDI) could be asymptomatic, mild or moderate diarrhea and fulminant colitis [2, 3].
2. Epidemiology of CDI
Center of Disease Control and Prevention showed an elevation in the incidence and the sever‐
ity of CDI [4]. More than 250,000 person need to be hospitalized due to CDI, and around 
14,000 people die from it in the United States every year [5]. Among hospitalized patients, 
the incidence of CDI differs every year and from location to another. It has been elevating, 
to nearly 15 per 1000 hospital dismissal [6] and around 20 cases per 100,000 individual in the 
community [7]. C. difficile can only colonize the gut when the normal intestinal microflora is 
changed by the usage of antibiotics and that was proved by the 16S ribosomal RNA sequenc‐
ing [8]. Therefore, the antibiotics usage remains the most important risk factors for C. dif-
ficile infection. Many antibiotics are associated with the CDI such as ampicillin, amoxicillin, 
cephalosporins, clindamycin, fluoroquinolones, trimethoprim and sulfonamides [9]. Another 
risk factor for CDI is the age; the severity of the infection increases as the age increases [10]. 
Poor hand hygiene has also previously been shown to play a part in CDI transmission [11]. 
Hospitalization considers also a main risk factor as it brings together many CDI risk factors 
in one place such as the use of antibiotics, the spore contaminated media, inappropriate hand 
hygiene and the elderly patients [12].
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3. C. difficile virulence factors
C. difficile has many virulence factors including toxins, sporulation, surface layer proteins and 
adherence. It produces many toxins such as the enterotoxin TcdA, the cytotoxin TcdB and the 
binary toxin CDT [12]. Theses toxins cause disruption of the actin cytoskeleton and tight junc‐
tion and cause a decrease in the transepithelial resistance, fluid accumulation and damage of 
the intestinal epithelium [13].
4. Diagnosis of CDI
Diagnosis of C. difficile is easily done in the laboratory and usually performed for the patients 
suffering from diarrhea. Currently, CDI is diagnosed by several available diagnostic tests 
such as enzyme immunoassay (EIA), EIA for C. difficile glutamate dehydrogenase (GDH) or by 
DNA‐based tests which recognize the genes of C. difficile toxin in the stool sample. Additional 
diagnostic tests are available like toxigenic cultures and cell culture neutralization assays [14].
Stool culture for C. difficile requires anaerobic culture and is not widely available [9]. 
Radiography suggestive of CDI includes polypoid mucosal thickening, haustral fold thicken‐
ing or gaseous distention of the colon; however, radiographic features are not sensitive and 
not CDI specific [15]. Another diagnostic method is the endoscopy which is rarely required, 
but it may be helpful in case of doubt of CDI from the clinical signs with all the laboratory 
tests showed negative results or in patients with inflammatory bowel disease [16].
5. Prevention and treatment of CDI
Since there is no effective vaccine for the CDI control, prevention of the CDI has been a 
demand and it has focused on barrier methods and environmental hygiene in a trial for pro‐
hibiting C. difficile spores and for the reduction of the CDI risk factors: isolation of CDI patient 
in private room, gowns and gloves usage, hand hygiene and the use of sporicidal solution for 
rooms [12]. Moreover, altering the antibiotic prescribing could be a good way for prevent‐
ing CDI spreading, since the possibilities of some antibiotics to stimuli CDI are smaller than 
others. Furthermore, the use of probiotics to prevent CDI could be a safe method. Probiotics 
usually formed of live microorganisms which give a lot of health benefits to the patient. These 
microorganisms work through direct activity against C. difficile through the inhibition of the 
bacterial adherence, the modification of the response of the host and the induction of produc‐
tion of specific IgA antitoxin [17, 18].
The treatment of CDI has not shown a big variation. For the acute infections, metronida‐
zole and oral vancomycin has been the mainstay of treatment since 1970. Fidaxomicin was 
approved in 2011 by the Food and Drug Administration for CDI treatment [19]. Treatment of 
the first recurrent CDI infection is recommended with a repeat course of either metronidazole 
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or vancomycin, and this regime is proved to be successful in 50% of patients [20]. Second 
recurrent infection can be treated with fidaxomicin which proved to prevent further episodes 
of C. difficile [21]. The fecal microbial transplantation is one of the bacterio‐therapy used to 
prevent CDI. It is referring to the infusion of fecal suspension from a healthy person to rein‐
stating the gut microbiota of the recipient.
6. Conclusion
Since the CDI causes common and serious problems, many researchers have focused on 
improving the prevention and the treatment of CDI. In this book, we have focused on study‐
ing the pathogenesis and the virulence factors of C. difficile including toxins and trying to 
explore the different diagnostic tools and preventive therapeutic methods.
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